Oncology and therapy
Cost-effectiveness of Nivolumab + Platinum Doublet Chemotherapy as Neoadjuvant Treatment for Resectable Non-Small Cell Lung Cancer in England.
Joel Russell, Mack Harris, Ariel Sun, Benjamin White, Thor-Henrik Brodtkorb, James Brockbank, Stefano Lucherini, Lien Vo, Sandra Milev
Published: 202510.1007/s40487-025-00397-5
Abstract
INTRODUCTION: This study aimed to assess the cost-effectiveness of neoadjuvant nivolumab + platinum doublet chemotherapy (PDC) versus relevant comparators in the treatment of patients with non-metastatic (stage IB-IIIA), resectable, non-small cell lu…
Preview only. Read the full abstract at the source